Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,308.68 Cr
Expense Ratio
2.1%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Meeta Shetty, Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | -2.95 | 21.94 | 17.22 |
| Nifty Pharma TRI | -6.84 | 20.8 | 13.97 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
30.2306
Last change
0.23 (0.7727%)
Fund Size (AUM)
₹ 1,308.68 Cr
Performance
11.96% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Meeta Shetty, Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.94 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 6.92 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.15 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 4.85 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 4.79 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.58 |
| ASTER DM HEALTHCARE LIMITED EQ | 4.4 |
| ALKEM LABORATORIES LIMITED EQ | 4.31 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 4.05 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 3.9 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 93.41 |
| Financial Services | 1.83 |
| Chemicals | 1.44 |
| Consumer Services | 0.76 |